CEO Severin Schwan told reporters on Thursday that Roche is in “a continued dialogue with the FDA. I wouldn’t be able to speculate what the outcome of this dialogue will be”.
He also revealed that Roche is planning to complete a phase 3 trial of the drug in the second half of 2022, adding that the “trial is a well-designed, very comprehensive trial so, whatever the outcome of this trial will be, we will have a definitive answer of what we can do for patients with this terrible disease so let’s keep fingers crossed”.
